Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 18, 2017

 

MetaStat, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation)

 

000-52735	20-8753132
(Commission File Number)	(IRS Employer Identification No.)

                                                                                                                                                                                       

27 Drydock Avenue, 2 nd Floor

Boston, MA 02210

(Address of principal executive offices and zip code)

 

[phone]

(Registrant's telephone number including area code)

 

 

(Registrant's former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01.  Entry into a Material Definitive Agreement.

 

On August 18, 2017, MetaStat, Inc. (“ MetaStat ”) received payment of $146,022 from Celgene Corporation (“ Celgene ”) for satisfactory completion of the third of four milestones pursuant to the pilot materials transfer agreement, as amended (the “ Research Agreement ”) between the parties.

 

MetaStat has successfully completed testing of Celgene’s proprietary materials in its nonclinical cell line models and is currently testing in its nonclinical animal models. Additionally, the term of the Research Agreement was extended by the parties through December 22, 2017. To date, MetaStat has received an aggregate of $876,134 from Celgene pursuant to the Research Agreement.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 




 

Dated: August 22, 2017

METASTAT, INC.     By: /s/ Douglas A. Hamilton        Name: Douglas A. Hamilton                Title: President and CEO